[Paperback]" />A Practitioner's Guide to Prescribing Antiepileptics and Mood Stabilizers for Adults with Intellectual Disabilities [Paperback]
A Practitioner's Guide to Prescribing Antiepileptics and Mood Stabilizers for Adults with Intellectual Disabilities [Paperback] is a new product in Computer Store. You can get special discount for A Practitioner's Guide to Prescribing Antiepileptics and Mood Stabilizers for Adults with Intellectual Disabilities [Paperback] only in this month. But, you can get special discount up to 30% only in this weeksProduct Details
- Paperback: 538 pages
- Publisher: Springer; 2012 edition (March 2, 2012)
- Language: English
- ISBN-10: 1461420113
- ISBN-13: 978-1461420118
Product Dimensions:
6.1 x 1.1 x 9.2 inches
- Shipping Weight: 1.8 pounds (View shipping rates and policies)
- Average Customer Review:5.0 out of 5 stars style="margin-left:-3px">See all reviews (2 customer reviews)
Editorial Reviews
From the Back Cover
Emotional, behavioral, and neuropsychiatric conditions are common in individuals with intellectual disabilities (IDs), most notably epilepsy, aggression, self-injurious behaviors, and bipolar and other mood disorders. Despite the prevalence of such problems, there is a scarcity in the literature of reliable information on medical treatments for those with IDs. A Practitioner's Guide to Prescribing Antiepileptics and Mood Stabilizers for Adults with Intellectual Disabilities provides a detailed framework for prescribing for this challenging population. Featuring the most up-to-date information on factors that inform prescribing, the Guide addresses basic issues and controversies (e.g., the rift between evidence-based and personalized medicine) in treating adults with cognitive deficits. Clients' specific needs are emphasized in developing appropriate and effective pharmacological intervention for improved outcomes and quality of life. Drugs discussed in the Guide include carbamazepine, clonazepam, diazepam, ethosuximide, felbamate, gabapentin, lacosamide, lamotrigine, levetiracetam, lithium, lorazepam, oxcarbazepine, phenobarbital, phenytoin, pregabalin, primidone, rufinamide, tiagabine, topiramate, valproate, and zonisamide. For each of these compounds, the guidelines cover: Indications for use; relative and absolute contraindications.Assessment during treatment; therapeutic drug monitoring; warning signs and symptoms for caretakers.Dosage: administration; initial and maximum recommended dosage; modifications associated with drug-drug interactions, personal characteristics, and (where appropriate) genetic variations.Adverse drug reactions: common, relatively uncommon, and potentially lethal, plus risk of metabolic syndrome.Guidelines for discontinuation.References, tables, and drug utilization reviews.A Practitioner's Guide to Prescribing Antiepileptics and Mood Stabilizers for Adults with Intellectual Disabilities is an indispensable decision-making reference for psychiatrists, neuropsychologists, psychopharmacologists, neurologists, internists, and clinical psychologists.
Customer Reviews
5.0 out of 5 stars
(2)
5.0 out of 5 stars
5 star
2
4 star
0
3 star
0
2 star
0
1 star
0
See both customer reviews
Share your thoughts with other customers
Write a customer review
Most Helpful Customer Reviews
1 of 1 people found the following review helpful
5.0 out of 5 starsBook Review: A Practitioner's Guide to Prescribing Antiepileptics and Mood Stabilizers for Adults with Intellectual DisabilitiesMay 10, 2012
By Ross J. Baldessarini, MD
Format:Paperback
Book ReviewA Practitioner's Guide to Prescribing Antiepileptics and Mood Stabilizers for Adults with Intellectual Disabilities, edited by Jose de Leon, M.D. with 12 coauthors. New York: Springer Media, 2012, 489 pages.This clinical compendium is edited by Jose de Leon, M.D., Professor at the Colleges of Medicine and Pharmacy of the University of Kentucky in Lexington, and Director of the Mental Health Research Center at Eastern State Hospital in Kentucky. He is an internationally recognized expert on the nature and treatment of neuropsychiatric disorders in persons with intellectual disabilities. This paperback volume summarizes current evidence-based knowledge required for sound clinical application of anticonvulsant and mood-stabilizing medicines for the treatment of adults with intellectual disability. It is organized into 23 chapters: the first on introductory principles and the basis of evidence used in preparing the book; 21 on specific medicines presented in alphabetical order; and one on the use of agents administered by routes other than by mouth. Each chapter is extensively referenced to the research literature backing each point, and the book is well indexed. Drugs discussed are: carbamazepine, clonazepam, diazepam, ethosuximide, felbamate, gabapentin, lacosamide, lamotrigine, levetiracetam, lithium, lorazepam, oxcarbazepine, phenobarbital, phenytoin, pregabalin, primidone, rufinamide, tiagabine, topiramate, valproate, and zonisamide. Each chapter is organized with a summary, an introduction on the nature of each drug and its uses, clinical indications with regulatory approval, unapproved ("off-label") clinical applications, contraindications and specific risks in particular medical disorders, recommended clinical and laboratory monitoring during treatment, dosing strategies, drug interactions, dosing adjustments required for other medicines, dosing adjustments for age, management of the challenging discontinuation process, and both common and uncommon adverse effects by organ-system and effect-type. Finally, each chapter provides a detailed tabulated, checklist of details required for safe and effective clinical application of each medicine. The authors make it clear that they have adhered to published, credible research of good quality to the extent possible, but that specific studies pertaining to the mentally retarded adult population, especially regarding long-term treatment, are rare. This circumstance requires relying on research on applications of the medicines discussed in patients with neurological (particularly epilepsy) and psychiatric disorders (particularly bipolar manic-depressive disorder) without specification of their cognitive status. Sensitivity to the importance of the evidence-base on which sound clinical practice relies is well indicated throughout the book. It reflects a remarkably sophisticated perspective on the value and limitations of currently fashionable efforts to place medical practice on an evidence-base, as discussed in a recent critical essay by Dr. de Leon (Evidence-based versus personalized medicine: are they enemies? Journal of Clinical Psychopharmacology 2011; 32: 153-163). Overall, this new book by Dr. de Leon and his twelve co-writers is well organized, scholarly, and filled with reliable and clinically relevant information not readily accessed elsewhere. It provides useful guidance for clinicians who care not only for the mentally retarded, but other neurological and psychiatric patients who are commonly treated with anticonvulsant and mood-stabilizing medicines.Ross J. Baldessarini, MDDirector, Psychopharmacology ProgramMcLean HospitalProfessor of Psychiatry and NeuroscienceHarvard Medical SchoolBoston, Massachusettts
Langganan:
Posting Komentar (Atom)
Tidak ada komentar:
Posting Komentar